Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • Senate passes elder fraud bill letting mutual funds pause redemptions
    • Latin American lender CAF ready to fund more rail: “There is money”
    • How Ashton Kutcher Built His Silicon Valley Investing Career
    • ETF Prime: VettaFi’s Kirsten Chang on Record ETF Year
    • The best and worst Bond films: ranked by critics and box office | James Bond
    • Sip & Stroll on Southbank canceled due to rain, flood risk
    • Bond ETFs Haven’t Been This Rewarding in Years, So Why Is Wall Street Dumping Them?
    • How to analyse a mutual fund? A beginner’s guide to returns, risk, costs and fund performance for better returns
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Bonds»Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal
    Bonds

    Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

    August 12, 2024


    Key Takeaways

    • Eli Lilly is selling bonds to fund the acquisition of drug developer Morphic. The sale is reportedly worth $5 billion.
    • The company’s stock was upgraded by Deutsche Bank analysts following its quarterly results last week.
    • Lilly shares jumped early in the day but closed in the red.

    Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.

    Deutsche Bank analysts called the drugmaker a “high growth unicorn” and upgraded its shares to a buy rating. The bump was based in part on sales of the weight-loss drug Mounjaro, which more than tripled to $3.09 billion when the company reported earnings last week

    The firm upgraded its price target to $1,025 from $725, a nearly 15% premium to Lilly’s Friday closing price. Shares rose above $904 Monday morning. 

    Bonds Help Fund Morphic Acquisition

    The stock gave back its early gains after Bloomberg in a report said the company would sell $5 billion in bonds to help pay for its $3.2 billion acquisition of Morphic (MORF). Lilly in a regulatory filing confirmed the sale but offered fewer details.

    The deal, announced last month, adds Morphic’s flagship developmental drug for inflammatory bowel disease to Lilly’s portfolio. The company is also developing molecules intended to treat autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer.

    Lilly will sell bonds in five chunks, including a 40-year note with a 1% higher yield than a U.S. Treasury note, according to the report. Corporate bonds are typically seen as riskier than U.S. government bonds, so they usually have higher interest rates to compensate.

    An Eli Lilly spokesperson declined to comment. Shares of the company closed Monday’s session down less than 1%,



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    The best and worst Bond films: ranked by critics and box office | James Bond

    November 19, 2026

    All 25 James Bond movies are being removed from Prime Video soon

    November 19, 2026

    Bond Girl Lea Seydoux Says ‘I Don’t Really Care’ Who Becomes 007’s New Female Lead

    November 19, 2026
    Leave A Reply Cancel Reply

    Top Posts

    All 25 James Bond movies are being removed from Prime Video soon

    November 19, 2026

    Latin American lender CAF ready to fund more rail: “There is money”

    November 19, 2026

    Senate passes elder fraud bill letting mutual funds pause redemptions

    November 19, 2026

    Empower Investments Surpasses $130 Billion in Separate Account Assets

    November 18, 2026
    Don't Miss
    Mutual Funds

    Senate passes elder fraud bill letting mutual funds pause redemptions

    November 19, 2026

    Financial Exploitation Prevention Act wins unanimous Senate approval as advisor groups press for White House…

    Latin American lender CAF ready to fund more rail: “There is money”

    November 19, 2026

    How Ashton Kutcher Built His Silicon Valley Investing Career

    November 19, 2026

    ETF Prime: VettaFi’s Kirsten Chang on Record ETF Year

    November 19, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Solana staking ETFs are ‘missing part of puzzle’: Bitwise CIO

    October 29, 2025

    Tax planning for mutual fund investments

    April 1, 2026

    Retail Investors Keep Pouring Money Into Mutual Funds Despite Prolonged Losses

    April 20, 2026
    Our Picks

    Senate passes elder fraud bill letting mutual funds pause redemptions

    November 19, 2026

    Latin American lender CAF ready to fund more rail: “There is money”

    November 19, 2026

    How Ashton Kutcher Built His Silicon Valley Investing Career

    November 19, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    🇮🇸 CPP Investments and Equinix complete atNorth acquisition to support growth of leading Nordic data center platform

    September 1, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.